COGT in the 13F filings
Cogent Biosciences Inc · CUSIP 19240Q201
- Quarter end
- 30 Jun 2025
- the date the book describes
- Filed
- 14 Aug 2025
- latest of these filings; the earliest 14 Aug 2025
- Managers listing it
- 3
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q1 2025 and Q2 2025; 3 listed it in both
- Shares listed
- 5,929,535
- combined, among listed positions
- Reported value
- $43m
- combined, at the quarter end
Among the 95 comparable managers: 0 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -1,070,550.
Managers listing COGT in Q2 2025
3 of 3 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Point72 Asset Management LP | 4,911,924 | $35m | 0.07% | Trimmed | -383,621 | 14 Aug 2025 (the filing on sec.gov) |
| Woodline Partners LP | 1,000,611 | $7.2m | under 0.1% | Trimmed | -686,929 | 14 Aug 2025 (the filing on sec.gov) |
| Farallon Capital Management LLC | 17,000 | $122k | under 0.1% | Held | 0 | 14 Aug 2025 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
No increase among listed positions.
Reductions
- Woodline Partners LPexisting position · 1,000,611 shares now-686,929
- Point72 Asset Management LPexisting position · 4,911,924 shares now-383,621
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 2 | $8.0m | n.a. | n.a. |
| Q1 2021 | 2 | $6.4m | n.a. | n.a. |
| Q2 2021 | 2 | $17m | n.a. | n.a. |
| Q3 2021 | 1 | $5.0m | n.a. | n.a. |
| Q4 2021 | 1 | $5.1m | n.a. | n.a. |
| Q1 2022 | 1 | $6.4m | n.a. | n.a. |
| Q2 2022 | 1 | $9.0m | n.a. | n.a. |
| Q3 2022 | 1 | $3.7m | n.a. | n.a. |
| Q4 2022 | 3 | $11m | n.a. | n.a. |
| Q1 2023 | 4 | $63m | n.a. | n.a. |
| Q2 2023 | 3 | $93m | n.a. | n.a. |
| Q3 2023 | 4 | $59m | n.a. | n.a. |
| Q4 2023 | 3 | $35m | 2 | 0 |
| Q1 2024 | 3 | $53m | 2 | 1 |
| Q2 2024 | 4 | $97m | 2 | 2 |
| Q3 2024 | 4 | $120m | 1 | 1 |
| Q4 2024 | 4 | $47m | 1 | 1 |
| Q1 2025 | 3 | $42m | 1 | 1 |
| Q2 2025 | 3 | $43m | 0 | 2 |
| Q3 2025 | 4 | $92m | 2 | 1 |
| Q4 2025 | 9 | $1.3bn | 24 | 5 |
| Q1 2026 | 11 | $1.6bn | 21 | 13 |
| Q2 2026 | 7 | $1.6bn | 17 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
COGT and LLY →COGT and JNJ →COGT and VRTX →Choose a stock to compare with COGT →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own COGT, latest filings →Back to the 13F Explorer →